• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur J Immunol . Characterization of the SARS-CoV-2-Specific T Cell Responses in Rheumatoid Arthritis Subjects Vaccinated for COVID-19 Protection

tetano

Editor, Senior Moderator
Eur J Immunol


. 2025 Dec;55(12):e70105.
doi: 10.1002/eji.70105. Characterization of the SARS-CoV-2-Specific T Cell Responses in Rheumatoid Arthritis Subjects Vaccinated for COVID-19 Protection

Jaeyoon Song[SUP] 1 [/SUP], Ricardo da Silva Antunes[SUP] 2 [/SUP], Mehrnaz Agili Seyede[SUP] 3 [/SUP], Monica Guma[SUP] 3 [/SUP], Alessandro Sette[SUP] 2 [/SUP], Alessandra Franco[SUP] 1 [/SUP]



Affiliations
Abstract

The efficacy of mRNA-based vaccines to prevent COVID-19 in autoimmune patients is controversial due to immunosuppressive therapies. Here, we characterized the T cell responses to SARS-CoV-2 in rheumatoid arthritis (RA) subjects, who received as few as one or up to seven vaccine injections. The study population had different disease severities and an association with other autoimmune comorbidities. All the subjects studied showed SARS-CoV-2 spike-specific CD4+ T helper (Th) cells in circulation, and in most of the subjects, CD8[SUP]+[/SUP] cytotoxic T cells. CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells were CCR6+, suggesting trafficking to tissues. T cell memory did not correlate with the number of vaccine boosts received. Nonspike-specific T cells were enumerated in subjects who had symptomatic or asymptomatic COVID-19. Spike- and nonspike-specific regulatory T cells (Treg) were detectable in most subjects. CD4[SUP]-[/SUP] CD8[SUP]-[/SUP] double-negative (DN) T cells expanded in response to SARS-CoV-2 peptides. DN T cells co-cultured with autologous myeloid dendritic cells (DC) differentiated into CD8[SUP]+[/SUP] T cells, depending upon the strength of the stimuli. RA subjects responded to mRNA-based vaccination for COVID-19 protection, with no correlation with the number of injections. DN T cells differentiated into CD8[SUP]+[/SUP] T cells after stimulation, potentially exacerbating inflammation in RA vaccine recipients.

Keywords: CD4−CD8− double negative (DN) T cells; SARS‐CoV‐2 vaccination in rheumatoid arthritis; T cell memory; regulatory T cells.

 
Back
Top Bottom